Protocols: CoLucid shares rocket up on positive migraine PhIII; Sage bags a 'breakthrough' on post-partum depression
Shares of Cambridge, MA-based CoLucid Pharmaceuticals $CLCD soared 90% Tuesday morning after the company declared a success for its Phase III study of the oral migraine drug lasmiditan. Investigators say that the drug scored on the primary as well as key secondary endpoints in their late-stage study. The primary endpoint tracked patients’ experience in the two hours after taking the drug, with the 100 mg and 200 mg dosing arms being pain free at roughly twice the 15% placebo response rate. About a third of all the patients, though, were washed out after failing to qualify for the modified ITT group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.